By Michael Susin


AstraZeneca said a late-stage study showed that its therapy for advanced or metastatic triple-negative breast cancer didn't meet its primary goals.

The British-Swedish pharma giant on Tuesday said the phase three trial for the use of Truqap plus chemotherapy showed that the treatment didn't meet the dual primary endpoints of improvement in overall survival when compared with the chemotherapy plus placebo. The study was applied in patients with inoperable or metastatic triple-negative breast cancer.

"Despite modest advances, triple-negative breast cancer remains one of the most challenging forms of disease to treat due to the lack of known actionable biomarker targets, and chemotherapy-based regimens continue to be the mainstay of treatment. While the CAPItello-290 trial results have not shown what we hoped, they provide important information to further understand this aggressive form of breast cancer where patients are in urgent need of new treatments," said Peter Schmid, the trial's main investigator.

However, the company added that Truqap is currently being evaluated in late stage trials for the treatment of breast cancer and prostate cancer in combination with established treatments.


Write to Michael Susin at michael.susin@wsj.com


(END) Dow Jones Newswires

06-18-24 0236ET